Table 2

Outcomes of patients treated with MPA and patients that were not treated with MPA

MPA
(n=49)
No MPA
(n=1928)
Age-sex adjustedPSOW adjusted *
Effect size (95% CI)P valueEffect size (95% CI)P value
Severity<0.0010.94
 Mild26 (53.1)1306 (67.7)1.00 (ref.)1.00 (ref.)
 Moderate14 (28.6)408 (21.2)3.57 (1.76 to 7.21)†<0.0011.18 (0.40 to 3.45) †0.77
 Severe9 (18.4)214 (11.1)8.02 (3.35 to 19.20)†<0.0011.18 (0.34 to 4.05) †0.79
Length of hospital stay, median (IQR)9.0 (4.0 to 19.0)10.0 (5.0 to 26.0)0.57 (0.33 to 0.98)‡0.0400.87 (0.41 to 1.84)‡0.72
Death6 (12.2)119 (6.2)11.58 (4.10 to 32.69)†<0.0011.38 (0.30 to 6.20)†0.67
  • Values are presented as n (percentage) unless otherwise indicated. Values, effect size and p values were calculated after handle missing data by simple imputation.

  • *Effect size and p values calculated using propensity score overlap weighting analyses, using no MPA treatment group as reference.

  • †OR calculated using multinomial or binary logistic regression models.

  • ‡Sub-HR (sHR) calculated among 645 hospitalised patients using Fine and Gray model with discharge alive as the event of interest and hospital death as the competing event. sHR >1 indicates an increase in length of hospital stay, and an sHR <1 indicates a decrease in length of hospital stay compared with the reference group.

  • MPA, mycophenolic acid; PSOW, propensity score overlap weighting.